Samphire Neuroscience

What Samphire Neuroscience does

Samphire Neuroscience is a UK-based neurotechnology company founded in 2021 that develops wearable transcranial Direct Current Stimulation (tDCS) devices targeted at women's hormone-related health conditions. Its core product is the Samphire Headband, sold as Nettle™—a CE-marked Class IIa medical device in the EU/UK—and as Lutea™, a general wellness product in the US (launched October 2025) that avoids FDA medical-device classification. The device delivers low-intensity electrical currents targeting the Prefrontal Cortex and Motor Cortex, the brain regions most affected by hormonal fluctuations, and is paired with a companion mobile app featuring My CycleSync™ technology that personalizes stimulation protocols to the user's cycle phase, symptoms, and life stage.

The company monetizes through one-time hardware device sales (Nettle™ and Lutea™), recurring consumables such as sponge refills and accessories, in-app subscriptions managed via RevenueCat across iOS and Android, and a newer enterprise B2B motion selling employer health-benefit packages at $900–$1,200 per employee annually. The company is also pursuing NHS trust reimbursement in the UK from 2028 onwards, supported by an active clinical trial portfolio across PMDD, endometriosis, perimenopause, and chronic migraine. Samphire operates dual legal entities (Samphire Neuroscience Ltd in the UK and Samphire Group Inc in Delaware) and distributes through DTC e-commerce, app stores, premium retail activations (Westfield London), and direct employer and clinician sales channels.

The company has raised approximately $7.3 million across multiple funding rounds through June 2025, including a $5 million Series A led by Finnish VC Inventure. Customer evidence includes 14,000+ pre-launch waitlist signups, 50,000+ stimulation sessions in the trailing 12 months, and clinical results showing over 30% anxiety reduction (twice placebo effect) in the ADAPT trial and 82.4% statistically significant luteal-phase anxiety reduction in PMDD patients. The company is led by co-founder and CEO Dr. Emilė Radytė and operates a small cross-functional team spanning science, product, and clinical functions.

Name

Samphire Neuroscience

Legal name

Samphire Neuroscience Ltd

Website

https://samphireneuro.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Samphire Neuroscience is a UK-based neurotechnology company founded in 2021 that develops wearable transcranial Direct Current Stimulation (tDCS) headbands—Nettle™ (EU/UK medical device) and Lutea™ (US wellness)—paired with a cycle-syncing companion app to treat PMS, PMDD, endometriosis, and perimenopausal symptoms in women.

Ownership category

akta.pro rank

Product category

Women's neurotechnology health devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Offices of Physical, Occupational and Speech Therapists, and Audiologists (62134), Scientific Research and Development Services (5417)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Women’s Health & Fertility Therapeutics (Digital) (HLACANAK)

akta.pro secondary industries

Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH), Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)

Keywords

• Neurostimulation devices
• Women's health technology
• Transcranial stimulation therapy
• Femtech neurotechnology
• Cycle-syncing brain health

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Infrastructure, Operations

Revenue model

1. Hardware Device Sales: Sale of Nettle™ headband (medical device in EU/UK) and Lutea™ headband (wellness device in US). These are one-time hardware purchases that provide the core neurostimulation functionality.
2. App/Subscription Services: Digital services through the companion mobile application providing cycle tracking, personalized insights, and protocol management. RevenueCat manages subscriptions through Apple App Store and Google Play Store.
3. Accessories and Consumables: Sale of accessories including sponge refills, Samphire Loop, travel cases, solution bottles, chargers, and tote bags. These provide ongoing revenue from the existing customer base.
4. Employer B2B Packages: Enterprise health benefit packages sold to employers. Pricing is per employee ($900-$1,200 per employee based on ROI calculator). Includes onboarding and support for workforce deployment.

Pricing tiers

Go-to-market motion4 records

Distribution channels7 records

Marketing channels7 records

Core offering

Samphire Neuroscience designs and sells a wearable transcranial direct current stimulation (tDCS) headband for women, sold as the CE-marked Class IIa medical device Nettle™ in the EU/UK and the general wellness product Lutea™ in the US. A companion mobile app with My CycleSync™ personalizes stimulation protocols to the user's cycle phase, symptoms, and life stage, targeting PMS, PMDD, dysmenorrhea, endometriosis-related pain, and perimenopausal/menopausal symptoms. Accessories (refills, charger, travel cases, solution bottle, tote bag, Samphire Loop) and clinical publications support the core offering.

Product overview

Samphire Neuroscience offers a portfolio of neurotechnology products for women's health, centered on the Samphire Headband available in two variants: Nettle™ (CE-marked Class IIa medical device for EU/UK) and Lutea™ (general wellness device for US). The core offering combines a wearable tDCS headband with a companion mobile app featuring My CycleSync™ technology that personalizes neurostimulation protocols based on the user's cycle phase and symptoms. The ecosystem includes accessories (refills, travel cases, charger, solution bottle, tote bag) and clinical publications (Healthcare Practitioners' Guide, Cycle Brain Guide). Products target conditions including PMS, PMDD, dysmenorrhea, endometriosis, perimenopause, and menopause.

Differentiator

Problem solved

Functional benefit

Brands

• Nettle™: CE-marked Class IIa medical device headband using transcranial direct current stimulation (tDCS) for treatment of PMS, PMDD, endometriosis, and menstrual pain. Available in UK and EU markets.
• Lutea™

Products and services

• Nettle™ Headband (EU/UK medical device) A CE-marked Class IIa medical device (EU/UK) delivering transcranial direct current stimulation (tDCS) through a wearable headband to treat symptoms of PMS, PMDD, menstrual pain, and other menstrual health conditions. Uses low-intensity electrical currents to modulate brain activity in the prefrontal cortex and motor cortex; self-administered via the companion app, worn 20 minutes daily during symptomatic periods.
• Lutea™ Headband (US wellness device) A general wellness wearable headband available in the US market delivering tDCS-based neurostimulation for wellbeing support. Unlike Nettle™, Lutea™ is not marketed or sold as a medical device and is not intended to treat or cure any disease or condition; FCC registered and HSA/FSA eligible via TrueMed.
• Samphire App (iOS and Android companion app) A companion mobile application that guides neurostimulation sessions, tracks menstrual cycles and symptoms, and delivers personalized health insights. Features My CycleSync™ technology that adapts headband protocols based on cycle phase, symptoms, and life stage, and integrates with Apple Health and Google Health Connect for health data synchronization.
• Samphire Loop An accessory for the Samphire headband device designed for easy attachment and use during neurostimulation sessions.
• Sponge Refills Replacement sponge consumables for the Samphire headband, required for maintaining proper electrical contact during neurostimulation sessions.
• Travel Case (UK & Europe) A protective travel case designed for the Nettle™ headband device for UK and European customers.
• Travel Case (US / International) A protective travel case designed for the Lutea™ headband device for US and international customers.
• Solution Bottle A bottle for preparing the conductive solution used with the Samphire headband sponges during neurostimulation sessions.
• Charger A charging device for the Samphire headband, shipped with EU, UK, and US adapters; a fully charged battery typically lasts 7–10 sessions or about one month of use.
• Tote Bag A branded tote bag accessory for carrying the Samphire headband and accessories.
• Employer Women's Health Benefit Package Enterprise B2B package sold to employers offering the Samphire Headband as a women's health benefit for their workforce. Priced at USD 900–1,200 per employee based on the company's ROI calculator, billed annually; includes onboarding and support, demos tailored to workforce demographics, and population-level ROI modeling.

Quantifiable outcome

• 87% of Samphire users say their 20 minutes a day changed their lives
• +6 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability4 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Queen Mary University of London (QMUL)coreStrategic or Co-development PartnerAcademic partnership for the ADAPT clinical trial evaluating the Samphire Headband for PMDD symptom management. Prof Paul Faulkner from QMUL conducted the trial which found 82.4% of women experienced statistically significant reduction in luteal-phase anxiety.
• NHS (London NHS Trusts)coreStrategic or Co-development PartnerNHS pilot with goal of NHS trust reimbursement for users in need from 2028 onwards. Active studies including ENHANCE (endometriosis-related chronic pelvic pain), RELIEF, and HOPE trials running through NHS healthcare system.
• UCLH (University College London Hospitals)coreStrategic or Co-development PartnerClinical partnership for active studies on PMDD follow-up, perimenopausal symptoms, and chronic pelvic pain. Part of the growing portfolio of clinical trials and healthcare system pilots.
• Westfield LondonminorGTM or Marketing PartnerPremium retail partnership for the 'Feel the Frequency' 11-day immersive wellness activation at The Village. Samphire participated as one of three wellness brands offering neurostimulation experiences as part of Westfield's expanded health and wellness proposition.
• Multiple International Research PartnersminorStrategic or Co-development PartnerVarious international clinical partnerships including studies on endometriosis, chronic pelvic pain, perimenopausal symptoms, and chronic migraine (MOSAIC trial).

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Flow Neuroscience: Direct peer offering a tDCS headset for at-home treatment of depression. Closely comparable on technology platform (transcranial direct current stimulation), regulatory pathway (Class IIa medical device), and direct-to-consumer + clinician distribution model.
• Maven Clinic: Women's and family health virtual care platform sold to employers as a benefit. Comparable on women's-health focus, B2B employer channel, and value proposition of reducing absenteeism and improving productivity for female employees.
• Natural Cycles: FDA-cleared digital platform for women's cycle and hormonal health, with a regulatory-cleared consumer medical device pathway. Comparable on women's hormonal health positioning and the combination of an app with cycle-personalized guidance.
• Hinge Health: Digital musculoskeletal therapy platform with employer B2B as its primary channel. Comparable on the digital-therapy + employer-health-benefits GTM motion and the thesis of measurable workforce productivity ROI.
• Livia: Consumer TENS device marketed for drug-free relief of menstrual pain. Closely comparable on the proposition of a non-pharmaceutical, wearable device addressing menstrual pain and women's health symptoms directly to consumers.
• Cala Health: Wearable neurostimulation therapy for chronic conditions (essential tremor, Parkinson's). Comparable on wearable electrical-nerve-stimulation technology, FDA regulatory pathway, and prescription-adjacent positioning for chronic symptomatic conditions.
• Big Health: Digital therapeutics for insomnia and anxiety sold through employers and health plans. Comparable on the digital-therapeutic positioning, B2B employer/health-plan channel, and clinical-evidence-led commercialization for mental health indications.
• Pelago (formerly Quit Genius): Digital therapeutic platform sold to employers and health plans for substance use and behavioral health. Comparable on the employer-channel digital-therapeutic business model and clinical-evidence-led value proposition.

Broad incumbents

• Elvie: Established women's health hardware brand (e.g., pelvic floor trainer, breast pump) sold direct-to-consumer. Comparable on women's health hardware DTC, brand-led marketing, and accessory/consumable ecosystem.
• Oura: Consumer wearable health device with subscription companion app for women's cycle, sleep, and readiness tracking. Comparable on consumer wearable + app subscription model, women's health feature set, and premium direct-to-consumer positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/samphireneuro
• LinkedInlinkedin.com/company/samphireneuro
• Instagraminstagram.com/samphireneuro

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds7 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Samphire Neuroscience